帕金森病中的益生菌,益生菌或协生菌补充剂:系统性审查和元分析与试验序列分析
Miguel Cabanillas-Lazo1, Milagros Pascual-Guevara1,2, Fabian A Chavez-Ecos1,3
1Grupo de Investigación Neurociencia, Metabolismo, Efectividad Clínica y Salud Pública (NEMECS), Universidad Científica del Sur, Lima, Peru.
Gerontology
|January 9, 2026
概括
益生菌,益生菌和协生菌可能通过改善便秘和运动症状,为帕金森病 (PD) 患者提供好处. 然而,需要更多高质量的研究来证实这些影响.
科学领域:
- 神经学 神经学
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 肠道微生物群的变化与帕金森病 (PD) 等神经系统疾病有关.
- 针对肠道微生物群的干预措施,如益生菌,益生菌或共生菌,正在探索用于PD症状管理.
- 这项研究系统地审查了这些干预措施在PD患者的疗效和安全性.
研究的目的:
- 评估益生菌,益生菌和共生菌在治疗帕金森病中的有效性和安全性.
- 综合当前关于肠道微生物群调节对PD症状影响的证据.
主要方法:
- 在2023年9月之前,对多个数据库进行了全面的系统搜索.
- 评估了研究质量,并使用元分析和叙事合成分析了数据.
- 使用GRADE评估证据的确定性,并对主要结果进行试验顺序分析.
主要成果:
- 对9项随机对照试验 (RCT) 的元分析,涉及3,608项确定的研究.
- 与安慰剂相比,干预表明便秘 (每周便,布里斯托尔尺度,药使用) 和运动症状 (UPDRS-III) 的潜在改善.
- 由于间接性和偏见风险,证据确定性非常低.
结论:
- 益生菌,益生菌和协生菌可能对帕金森病患者的便秘和运动症状有好处.
- 证据的确定性从非常低到中等不等.
- 进一步高质量的研究是必要的,以证实这些发现,并建立强有力的证据临床应用.
相关概念视频
Parkinson's Disease: Treatment
970
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
970
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631
Drugs for Treatment of Diarrhea-Predominant IBS
618
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
618

